Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr.

J Clin Oncol. 2001 Sep 15;19(18):3852-60.

PMID:
11559723
2.
3.

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ.

Blood. 1999 Nov 15;94(10):3315-24.

4.

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.

Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1479-84. doi: 10.1016/j.bbmt.2009.07.010. Epub 2009 Sep 1.

5.

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M.

J Clin Oncol. 2011 Jul 10;29(20):2753-7. doi: 10.1200/JCO.2010.32.2107. Epub 2011 Jun 6.

PMID:
21646615
6.

Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.

Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F.

Haematologica. 2002 May;87(5):485-9.

7.

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.

Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R, Ohnishi K.

Int J Hematol. 2005 Oct;82(3):224-9.

PMID:
16207595
8.

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.

Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N.

Ann Oncol. 2006 Jan;17(1):131-4. Epub 2005 Oct 14.

PMID:
16227315
9.

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr.

N Engl J Med. 1998 Nov 5;339(19):1341-8.

10.

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.

Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R.

Leukemia. 2002 Apr;16(4):617-22.

11.

Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.

Wang H, Hao L, Wang X, Li J, Wu Q, Bian S.

Int J Hematol. 2010 Jun;91(5):820-5. doi: 10.1007/s12185-010-0575-z. Epub 2010 May 13.

PMID:
20461563
12.

Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.

Carmosino I, Latagliata R, Avvisati G, Breccia M, Finolezzi E, Lo Coco F, Petti MC.

Haematologica. 2004 May;89(5):615-7.

13.

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.

Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE.

Br J Haematol. 2015 Nov;171(4):471-7. doi: 10.1111/bjh.13607. Epub 2015 Jul 24.

14.

Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.

Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J.

Cancer. 2013 Jan 1;119(1):115-25. doi: 10.1002/cncr.27650. Epub 2012 Aug 28.

15.

Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.

Bergstrom SK, Gillan E, Quinn JJ, Altman AJ.

J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):545-7.

PMID:
9856675
16.

Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.

Song X, Hu X, Lü S, Gao L, Chen L, Yang J, Zhang W, Wang J.

Eur J Haematol. 2014 Jul;93(1):54-62. doi: 10.1111/ejh.12301. Epub 2014 Apr 1.

PMID:
24592821
17.

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.

Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, Liu X, Han X, Hu L, Wang S, Zhao Y, Zhang Y, Fan S, Lv C, Li L, Zhu L.

Blood. 2010 Mar 4;115(9):1697-702. doi: 10.1182/blood-2009-07-230805. Epub 2009 Dec 22.

18.

Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ.

J Clin Oncol. 2013 Nov 20;31(33):4215-21. doi: 10.1200/JCO.2013.48.8312. Epub 2013 Oct 14.

PMID:
24127444
19.

Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.

Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group.

Blood. 2013 Apr 18;121(16):3095-102. doi: 10.1182/blood-2012-11-466862. Epub 2013 Feb 14.

20.

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.

Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J.

Cancer. 2003 May 1;97(9):2218-24.

Supplemental Content

Support Center